Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
PrEP is being incorporated into national HIV-prevention strategies in African countries, with key at-risk populations being prioritized. Expansion of these programs will require better access to and communication about these therapies.
The Cancer Core Europe centers share their experience on caring for patients with cancer during the COVID-19 pandemic ― a time of challenges and opportunities for cancer health professionals, researchers and patients alike.
The emerging success of neoadjuvant therapy is creating opportunities for understanding successful immune responses and improving therapies using this unique pool of knowledge.
The authors argue for a consistent weight-management approach, alongside an assessment of the risk for developing cardiometabolic diseases as a prevention strategy.
Amit and colleagues discuss where single-cell genomic technologies can be applied both in trial design and in the clinical trial stage to improve the development of immunotherapies.